Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS: NWBO · Delayed Price · USD
0.477
+0.017 (3.67%)
Apr 25, 2024, 3:59 PM EDT - Market closed
Northwest Biotherapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Year | Current | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 - 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Capitalization | 568 | 789 | 797 | 611 | 1,109 | 118 | 92 | 58 | 39 | 249 | 317 | Upgrade
|
| Market Cap Growth | - | -0.94% | 30.33% | -44.89% | 836.40% | 28.22% | 58.54% | 49.92% | -84.37% | -21.55% | 155.83% | Upgrade
|
| Enterprise Value | 611 | 833 | 816 | 634 | 1,119 | 136 | 87 | 90 | 64 | 249 | 329 | Upgrade
|
| PE Ratio | -10.73 | -12.61 | -5.82 | 3.41 | -2.06 | -5.03 | -2.58 | -0.80 | -0.48 | -2.17 | -2.34 | Upgrade
|
| PS Ratio | 293.80 | 408.63 | 473.52 | 608.42 | 859.37 | 49.16 | 224.28 | 173.46 | 62.40 | 143.00 | 218.00 | Upgrade
|
| PB Ratio | -17.28 | -16.81 | -6.22 | -4.93 | -3.06 | -2.72 | -1.96 | -1.23 | -1.47 | -53.18 | -9.05 | Upgrade
|
| P/FCF Ratio | -14.23 | -13.83 | -14.31 | -13.80 | -28.67 | -3.68 | -2.66 | -1.60 | -0.64 | -2.91 | -3.59 | Upgrade
|
| P/OCF Ratio | -15.14 | -14.72 | -15.10 | -15.97 | -34.57 | -3.72 | -2.67 | -1.60 | -0.70 | -3.16 | -5.81 | Upgrade
|
| EV/Sales Ratio | 316.28 | 431.11 | 484.98 | 631.08 | 867.02 | 56.49 | 211.11 | 266.65 | 102.51 | 142.96 | 226.44 | Upgrade
|
| EV/EBITDA Ratio | -15.78 | -15.49 | -12.43 | -12.02 | -12.99 | -4.96 | -2.00 | -1.58 | -0.75 | -1.97 | -2.74 | Upgrade
|
| EV/EBIT Ratio | -15.29 | -15.01 | -12.16 | -11.89 | -12.92 | -5.01 | -1.94 | -1.57 | -0.75 | -1.97 | -2.74 | Upgrade
|
| EV/FCF Ratio | -14.99 | -14.59 | -14.66 | -14.31 | -28.92 | -4.23 | -2.50 | -2.45 | -1.05 | -2.91 | -3.73 | Upgrade
|
| Debt / Equity Ratio | -0.88 | -0.88 | -0.20 | -0.31 | -0.05 | -0.41 | -0.36 | -0.66 | -1.18 | -4.65 | -0.73 | Upgrade
|
| Debt / EBITDA Ratio | -0.84 | -0.85 | -0.40 | -0.72 | -0.23 | -0.66 | -0.39 | -0.56 | -0.37 | -0.17 | -0.21 | Upgrade
|
| Debt / FCF Ratio | -0.80 | -0.80 | -0.47 | -0.86 | -0.51 | -0.56 | -0.48 | -0.86 | -0.51 | -0.25 | -0.29 | Upgrade
|
| Quick Ratio | 0.05 | 0.05 | 0.06 | 0.11 | 0.03 | 0.01 | 0.32 | 0.00 | 0.08 | 0.34 | 0.19 | Upgrade
|
| Current Ratio | 0.09 | 0.09 | 0.07 | 0.13 | 0.04 | 0.08 | 0.34 | 0.02 | 0.10 | 0.37 | 0.21 | Upgrade
|
| Asset Turnover | 0.06 | 0.07 | 0.05 | 0.03 | 0.04 | 0.26 | 0.02 | 0.01 | 0.01 | 0.02 | 0.02 | Upgrade
|
| Interest Coverage | -12.20 | -10.04 | -11.07 | -10.52 | -10.14 | -9.23 | -4.20 | -9.86 | -20.76 | -30.41 | -101.55 | Upgrade
|
| Return on Equity (ROE) | 132.47% | 133.26% | 106.83% | -144.47% | 148.33% | 54.11% | 75.90% | 154.66% | 302.71% | 2453.83% | 387.23% | Upgrade
|
| Return on Assets (ROA) | -222.69% | -224.02% | -436.89% | 446.03% | -1636.42% | -258.21% | -145.11% | -149.56% | -151.62% | -162.07% | -232.09% | Upgrade
|
| Return on Capital (ROIC) | 3920.06% | 3920.06% | 65.96% | 59.75% | 25.24% | 107.55% | 136.62% | 344.67% | -1696.62% | -740.06% | 1080.01% | Upgrade
|
| Earnings Yield | -10.96% | -7.93% | -17.17% | 29.29% | -48.53% | -19.90% | -38.74% | -125.49% | -206.33% | -46.14% | -42.79% | Upgrade
|
| FCF Yield | -10.06% | -7.23% | -6.99% | -7.25% | -3.49% | -27.19% | -37.64% | -62.63% | -155.85% | -34.32% | -27.86% | Upgrade
|
| Buyback Yield / Dilution | -7.74% | -10.17% | -0.79% | -38.99% | -28.53% | -28.22% | -81.19% | -118.63% | -42.93% | -31.17% | -80.28% | Upgrade
|
| Total Shareholder Return | -7.74% | -10.17% | -0.79% | -38.99% | -28.53% | -28.22% | -81.19% | -118.63% | -42.93% | -31.17% | -80.28% | Upgrade
|
Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.